Printer Friendly

PROCTER & GAMBLE TO ACQUIRE ROEHM PHARMA

 PROCTER & GAMBLE TO ACQUIRE ROEHM PHARMA
 CINCINNATI, May 8 /PRNewswire/ -- The Procter & Gamble


Company (NYSE: PG) and Roehm GmbH of Darmstadt, Germany, a Huels Company, today announced that Procter & Gamble will acquire Roehm GmbH's share of Roehm Pharma, a joint venture dating back to 1960. Procter & Gamble currently owns 50 percent of Roehm Pharma. Under the agreement, P&G will take over the prescription drugs, vaccines and diagnostic products business, and Roehm Pharma's Industrial Coating business will be returned to Roehm GmbH. The acquisition is subject to approval by Roehm shareholders and German government authorities.
 Roehm Pharma was founded in 1960 as a joint venture of Roehm GmbH and Smith Kline & French (SKF), of Philadelphia. In 1975, Norwich Eaton Pharmaceuticals Inc. purchased SKF's interest in Roehm Pharma. In 1982, Procter & Gamble acquired Norwich Eaton, and earlier this year changed its name to Procter & Gamble Pharmaceuticals.
 Roehm Pharma has annual net sales of approximately $125 million, primarily in Europe, from pharmaceuticals, vaccines, diagnostic tests, and industrial coatings. Among its pharmaceutical products, Dytide H is the leading diuretic in Germany for the treatment of hypertension.
 "This is another important step in expanding our global pharmaceutical business," said Edwin L. Artzt, Chairman and Chief Executive of Procter & Gamble. "Roehm Pharma's management and employees have built a strong business in Germany. Combined with our current P&G Pharmaceuticals operations in France, Belgium, Italy, the Netherlands, and the U.K., we have a solid base upon which to build for the future in the important European market."
 Dr. H. Teitge, General Manager of Roehm GmbH, said the core business of Roehm GmbH is industrial chemicals and the acquisition of Roehm Pharma's pharmaceutical business by P&G will allow each company to focus on its area of principal interest. Roehm's strategy is completely directed to the innovation and expansion of highly finished special products. These industrial products, particularly EUDRAGIT, are an important Roehm development based on Methylmethacrylate which is an acrylic coating.
 Procter & Gamble and Roehm GmbH expect that business will proceed as usual during the transition.
 Procter & Gamble, based in Cincinnati, makes and markets a wide range of products for consumers and institutional use including pharmaceutical and over-the-counter health care products.
 Since the end of 1989, Roehm GmbH, a member of the Huels Group, produces and markets worldwide chemical speciality products, among which is the well-known plastic Plexiglass. This product is sold under the Acrylite trademark in the Western Hemisphere.
 -0- 5/8/92
 /CONTACT: Ruth A. Behrens of Procter & Gamble Pharmaceuticals, Norwich, NY, 607-335-2531/
 (PG) CO: Procter & Gamble; Roehm GmbH ST: Ohio; Germany IN: HOU SU: TNM


LC -- CL003 -- 7989 05/08/92 09:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 8, 1992
Words:442
Previous Article:NATIONSBANK BANK ANNOUNCES CUSTOMER APPRECIATION WEEK MAY 11-15
Next Article:LCS INDUSTRIES ANNOUNCES THE ELECTION OF A NEW DIRECTOR
Topics:


Related Articles
PFIZER AND PROCTOR & GAMBLE SIGN AGREEMENT ON OSTEOPOROSIS TREATMENT DRUG
ROBERTS PHARMACEUTICAL COMPLETES UNITED KINGDOM PRODUCT ACQUISITION FROM PROCTER & GAMBLE
HYDRON TECHNOLOGIES AND NYCOMED PHARMA ANNOUNCE INTENT TO DISTRIBUTE PRODUCTS IN SCANDINAVIA
U.S. FDA Grants Marketing Approval of Actonel(R) for Prevention and Treatment of Osteoporosis.
ACTONE OFFERED FOR PREVENTION/TREATMENT OF OSTEOPOROSIS.
STUDY SHOWS RISEDRONATE PROVIDES A SIGNIFICANT AND SUSTAINED 5-YEAR FRACTURE-REDUCTION BENEFIT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS.
New Data Show Actonel(R) Reduced Clinical Vertebral Fractures In As Early as Six Months.
New Data Show Actonel(R) Reduced Clinical Vertebral Fractures In As Early as Six Months.
Study Shows Actonel(R) Reduces Vertebral Fracture Risk 70 Percent in Patients on Chronic Steroid Therapy.
In a New Study Actonel(R) 35 mg Once-a-Week Was as Effective as 5 mg Daily In Postmenopausal Women.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters